N o n -c o m m e r c i a l u s e o n l y
In order to find out the prevalence of ESUS in reallife condition in Italy, all patients admitted to our stroke unit who underwent extensive diagnostic search were reassessed to identify those who could match the criteria of ESUS. Recurrences in patients with ESUS, cryptogenic stroke, and cardioembolic stroke in a mean follow-up time of 2 years were also compared.
Materials and Methods
According to our protocol since 2010 all patients routinely perform an hyperacute brain CT followed by a 48-72 h delayed brain CT, a 12-lead EKG plus a 72 h continuous cardiac monitoring, a precordial echocardiography, and a cervical duplex ultrasonography. Transcranial Doppler ultrasonography and/or CT angiography follow when indicated.
All data is prospectively stored in a stroke registry. In this study we retrospectively reassessed the diagnosis of 391 patients admitted in a 30-month period from May 2010 to December 2012 ( Figure 1 Embolic stroke of undetermined source 
Results
Within a 2-year follow-up (mean time: 25.44 months -standard deviation: 9.42), 5 new ischemic cerebrovascular events occurred in the group of cardioembolic strokes (incidence 3.5% per year) and 5 in the group of cryptogenic strokes (incidence 2.6% per year). Four out of five recurrences in cryptogenic strokes occurred in patients matching the criteria of ESUS.
Cryptogenic stroke non-ESUS had 1 recurrence (incidence=1.2% per year): the patient had cardioembolic recurrent stroke following paroxysmal atrial fibrillation (AF) and myocardial infarction (MI). She had moderate diastolic dysfunction at first event and was in antiplatelet therapy.
ESUS patients had 4 recurrences (incidence=4.2% per year): i) 1 patient had embolic recurrent stroke following paroxysmal AF and auricular thrombus. She had moderate systolic dysfunction at first event and was in antiplatelet therapy; ii) 2 patients had cryptogenic recurrent strokes. They both were in antiplatelet therapy and had moderate systolic or diastolic dysfunction associated with slight-to-moderate atrial enlargement (1) or mitral prolapse (1) at first event; iii) 1 patient had a vertebral-basilar TIA. She had mitralannular-calcification plus moderate atrial enlargement and took double antiplatelet therapy.
Cardioembolic strokes had 5 recurrences (incidence=3.5% per year). All recurrences were cardioembolic: i) 2 patients were in VKA therapy for AF and their international normalized ratio was in therapeutic range (recurrence rate 3.9% per year); ii) 3 patients were in antiplatelet therapy despite paroxysmal AF or MI at first event (recurrence rate 3.2% per year).
Discussion and Conclusions
We performed retrospective analysis of real-life data from a single stroke unit registry in which an extensive diagnostic protocol (including precordial echocardiography and a 72-h long continuous EKG monitoring) has been routinely performed. Cardioembolic etiology was found in 28% of all strokes. The extensive search may explain the high rate of cardioembolic strokes that is around the top end of the range reported in literature (14%-30%). 
N o n -c o m m e r c i a l u s e o n l y
Excluding strokes with plausible dual etiology (8%), cryptogenic (no lacunar) strokes represented about 30% of the total. Patients who matched the criteria of ESUS represented 10.5% of all strokes, the same as reported by Ntaios in the Athens Stroke Registry. 7 Features of the cohort of patients meeting the ESUS criteria are reported in Table 1 . Our patients are old and female. Hypertension is the most frequent risk factor followed by dyslipidemia, diabetes, coronary heart disease, and prior stroke/TIA. The Athens Registry and the few studies analyzed by Hart widely differed and a typical pattern of demographic or risk factors in patients with ESUS is still unknown. Among minor-risk embolic sources, systolic or diastolic dysfunctions are the most common (77%) followed by mitral valve calcification (25%). That can be related to the advanced age of our patients (about 77 years).
In literature recurrence in cryptogenic strokes ranges from 3% to 6% per year depending on the different diagnostic criteria adopted.
1 ESUS recurrence rate is reported to be similar to that that of cardioembolic strokes and higher than that of non-cardioembolic strokes. 8 In our experience cryptogenic stroke as a whole had a recurrence rate of 2.6% per year, the same as reported in the German Stroke Registry (2.2%-2.8%).
9,10 Our patients with ESUS had a recurrence rate of 4.4% per year (Figure 3) , slightly higher than that of cardioembolic stroke (3.5%) and significantly higher than that of cryptogenic not-ESUS 1.2% (P<0.0001). This is the first description of a cohort of ESUS patients in an Italian stroke unit. Our experience has limitations. This is a single-center analysis and the small number of patients reduces the value of statistical analysis. The diagnostic assessment of aortic arch and of intracranial artery was performed on clinical basis and some patients could have been excluded from the diagnosis of ESUS. The OAC therapy was prescribed in 56.9% of patients with cardioembolic strokes (the same rate reported in literature), 6 but only VKA was administrated because NOACs were not yet available in our country at that time.
However, our results confirm that patients with ESUS have a significantly higher risk of recurrence than those with non-ESUS cryptogenic strokes, and a slightly higher risk than those with cardioembolic strokes. Remarkably ESUS recurrences showed a typical cardioembolic source only in one out of four patients. That is interesting and needs further investigation.
Our results support the hypothesis that a more extensive diagnostic evaluation should be carried out in cryptogenic strokes. Presently, main stroke guidelines [American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO)] do not recommend echocardiography in diagnostic assessment of stroke. However, to diagnose an ESUS, echocardiography and prolonged rhythm monitoring are mandatory.
Aspirin or other antiplatelet agents are recommended in non-cardioembolic stroke but no specific therapy is suggested for cryptogenic stroke. 11, 12 As a subgroup of cryptogenic strokes, ESUS includes a Embolic stroke of undetermined source Navigate ESUS 14 and The Atticus study 15 ) are ongoing to test the effectiveness and safety of NOAC in the prevention of recurrent stroke in patients with ESUS. We hope their results will contribute in improving the efficacy of secondary prevention in this subgroup of cryptogenic stroke.
